PTCT
PTCT
NASDAQ · Biotechnology

Ptc Therapeutics Inc

$73.69
+9.20 (+14.27%)
As of May 9, 1:16 AM ET ·
Financial Highlights (FY 2026)
Revenue
1.56B
Net Income
613.86M
Gross Margin
97.3%
Profit Margin
39.4%
Rev Growth
+35.3%
D/E Ratio
848.93
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 97.3% 97.3% 60.4% 60.4%
Operating Margin 50.1% 45.1% 19.1% 18.3%
Profit Margin 39.4% 37.5% 16.6% 18.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.56B 1.15B 623.61M 650.14M
Gross Profit 1.51B 1.12B 376.75M 392.78M
Operating Income 779.53M 518.54M 119.04M 119.01M
Net Income 613.86M 408.33M 103.27M 119.61M
Gross Margin 97.3% 97.3% 60.4% 60.4%
Operating Margin 50.1% 45.1% 19.1% 18.3%
Profit Margin 39.4% 37.5% 16.6% 18.4%
Rev Growth +35.3% +35.3% +11.8% -7.9%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 2.92B 2.92B 693.46M 831.94M
Total Equity 3.44M 3.44M 3.87B 4.02B
D/E Ratio 848.93 848.93 0.18 0.21
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 795.72M 558.71M 195.81M 183.50M
Free Cash Flow 61.49M 67.39M